Is SANOFI.NS overvalued or undervalued?

SANOFI.NS currently has a P/E ratio of 20.95. Relative to the sector average of 43.00, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Sanofi India Limited stock?

Sanofi India Limited trades on NSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of SANOFI.NS?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying SANOFI.NS protect my money against local inflation?

Many investors in Latin America buy international stocks like SANOFI.NS to protect their purchasing power. Because SANOFI.NS is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy SANOFI.NS shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is SANOFI.NS a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well SANOFI.NS diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocksSANOFI.NS

Sanofi India Limited

₹2,945.40-₹34.30-1.15%

NSE / INR

Market cap

₹67.8B

P/E

20.9

EPS (TTM)

₹1.56

Dividend yield

4.18%

Beta

0.20

1Y return

-37.51%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$397M2021

$334M2022

$240M2023

$235M2024

$204M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.02Low
Current ratio1.69
Cash ratio0.63
Net margin17.9%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

SANOFI.NS20.9
Healthcare sector median43.0
S&P 50022.0

Trades about 51% below its sector, cheaper than its peers on earnings.

Ratios

PEG-5.16
Price to book8.21
EPS (TTM)₹1.56
Payout ratio4,162%
FCF yield4.52%

Range & risk

₹2914.10₹4898.00

Trading in the lower third of its 52-week band

Beta0.20

Profile

What Sanofi India Limited actually does

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

CEO

Deepak Arora

Employees

1,097

Headquarters

Mumbai, MH

Founded

1994-11-03

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save SANOFI.NS and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

SANOFI.NS has a beta of 0.20, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Sanofi India Limited